These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 12721933)

  • 1. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.
    Hunt PW; Martin JN; Sinclair E; Bredt B; Hagos E; Lampiris H; Deeks SG
    J Infect Dis; 2003 May; 187(10):1534-43. PubMed ID: 12721933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection.
    Kaufmann GR; Zaunders JJ; Cunningham P; Kelleher AD; Grey P; Smith D; Carr A; Cooper DA
    AIDS; 2000 Dec; 14(17):2643-51. PubMed ID: 11125882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The independent effect of drug resistance on T cell activation in HIV infection.
    Hunt PW; Deeks SG; Bangsberg DR; Moss A; Sinclair E; Liegler T; Bates M; Tsao G; Lampiris H; Hoh R; Martin JN
    AIDS; 2006 Mar; 20(5):691-9. PubMed ID: 16514299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
    Benito JM; López M; Lozano S; González-Lahoz J; Soriano V
    J Infect Dis; 2008 Nov; 198(10):1466-73. PubMed ID: 18847371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection.
    Dyrhol-Riise AM; Voltersvik P; Olofsson J; Asjö B
    AIDS; 1999 Dec; 13(17):2365-76. PubMed ID: 10597778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
    Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
    J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
    Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
    AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy.
    Ostrowski SR; Katzenstein TL; Thim PT; Pedersen BK; Gerstoft J; Ullum H
    J Infect Dis; 2005 Feb; 191(3):348-57. PubMed ID: 15633093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
    d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
    J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
    Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
    J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.
    D'Amico R; Yang Y; Mildvan D; Evans SR; Schnizlein-Bick CT; Hafner R; Webb N; Basar M; Zackin R; Jacobson MA
    J Clin Immunol; 2005 Mar; 25(2):106-15. PubMed ID: 15821887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial.
    Lebouché B; Jenabian MA; Singer J; Graziani GM; Engler K; Trottier B; Thomas R; Brouillette MJ; Routy JP
    Trials; 2014 Oct; 15():390. PubMed ID: 25293882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
    Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
    Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.
    Wu H; Connick E; Kuritzkes DR; Landay A; Spritzler J; Zhang B; Spear GT; Kessler H; Lederman MM;
    AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1231-40. PubMed ID: 11559422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection.
    Lange CG; Lederman MM; Madero JS; Medvik K; Asaad R; Pacheko C; Carranza C; Valdez H
    J Acquir Immune Defic Syndr; 2002 May; 30(1):33-40. PubMed ID: 12048361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children.
    Resino S; Galán I; Bellón JM; Navarro ML; León JA; Muñoz-Fernandez MA
    J Clin Immunol; 2003 Jul; 23(4):279-89. PubMed ID: 12959220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
    Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
    J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.